Related references
Note: Only part of the references are listed.Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers
Maite de la Forest Divonne et al.
JOINT BONE SPINE (2017)
Dosing down with biologic therapies: a systematic review and clinicians' perspective
Christopher J. Edwards et al.
RHEUMATOLOGY (2017)
Validation of FLARE-RA, a Self-Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare
Bruno Fautrel et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
Judith Haschka et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
Bruno Fautrel et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment
Juergen Rech et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study
Hisashi Yamanaka et al.
MODERN RHEUMATOLOGY (2016)
Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry
Kazuki Yoshida et al.
RHEUMATOLOGY (2016)
Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics A Systematic Review
Francine Chingcuanco et al.
ANNALS OF INTERNAL MEDICINE (2016)
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Georg Schett et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis
Tais Freire Galvao et al.
CLINICAL RHEUMATOLOGY (2016)
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
Johannes W. J. Bijlsma et al.
LANCET (2016)
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity
Marjan Ghiti Moghadam et al.
ARTHRITIS & RHEUMATOLOGY (2016)
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Katerina Chatzidionysiou et al.
RMD OPEN (2016)
Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission
Stefano Alivernini et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study
Kazuki Yoshida et al.
JOURNAL OF RHEUMATOLOGY (2015)
Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review
T. Martijn Kuijper et al.
JOURNAL OF RHEUMATOLOGY (2015)
Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary
Susan J. Bartlett et al.
JOURNAL OF RHEUMATOLOGY (2015)
Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis
Esperanza Naredo et al.
RHEUMATOLOGY (2015)
Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
David L. Scott et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
Noortje van Herwaarden et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
David L. Scott et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
Noortje van Herwaarden et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
Jaana T. Joensuu et al.
PLOS ONE (2015)
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
Josef S. Smolen et al.
LANCET (2014)
Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study
Aatke van der Maas et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis
Iris Navarro-Millan et al.
CLINICAL THERAPEUTICS (2013)
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study
N. B. Klarenbeek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Developing a Standardized Definition for Disease Flare in Rheumatoid Arthritis (OMERACT 9 Special Interest Group)
Clifton O. Bingham et al.
JOURNAL OF RHEUMATOLOGY (2009)
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
D. van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2007)
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis - Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Share Paper
